Northamptonshire nurse embraces full multimodal treatment after breast cancer diagnosis
Susan Royse’s breast cancer diagnosis arrived after she noticed a small lump in her left breast early in the year. At first, she assumed the change might be linked to hormone shifts. When the lump enlarged and became painful, she sought help and was referred immediately. The sequence is familiar in breast oncology: a subtle physical change, then a rapid escalation once a lesion behaves like something malignant rather than benign.
Her diagnosis was grade 3 invasive ductal carcinoma, with hormone receptor-positive and HER2-positive biology, a combination often described as triple-positive breast cancer. In practical terms, that profile matters because it opens the door to multiple treatment pathways at once. Surgery removes the known primary disease, chemotherapy attacks microscopic spread, endocrine therapy suppresses the hormonal signaling that can feed tumor growth, and HER2-targeted therapy blocks a major proliferative driver. For patients with this subtype, treatment is rarely a single intervention. It is usually a coordinated sequence.
Royse, a cardiology specialist nurse at Northampton General Hospital, had a lumpectomy and lymph node removal in June. She completed chemotherapy on Thursday and will begin radiotherapy in December, alongside HER2-targeted and hormone-blocking treatment. Her description of choosing “the whole shebang” reflects the logic of modern breast cancer care: when a tumor carries multiple actionable vulnerabilities, oncology teams often use every available lever rather than relying on one modality alone.
The diagnosis was especially jarring because Royse works in acute and emergency care and has spent 24 years as a nurse. She said her mind immediately moved toward worst-case scenarios. That reaction is hardly unusual. Healthcare workers may know the diagnostic pathways, but clinical knowledge does not blunt fear when the diagnosis becomes personal. In many patients, breast cancer is not only a threat to health; it also disrupts work, identity, family roles, and the sense of control that daily routines usually provide.
Royse said she did not tell the treatment team that she was a nurse at first. The clinicians eventually worked it out as she asked detailed questions and demonstrated familiarity with the process. Her experience is a reminder that even medically literate patients should not be expected to manage alone. Cancer care depends on clear explanations, repetition when needed, and enough time for questions to surface. In her account, the chemotherapy nurses answered every concern with “absolute clinical accuracy,” a phrase that speaks to the importance of precise communication when patients are navigating toxicities, timelines, and uncertainty.
Chemotherapy is physically and emotionally demanding, and breast cancer treatment often extends beyond the infusion chair. Fatigue, nausea, hair loss, infection risk, and neuropathy can accumulate across cycles. Surgery can leave its own burden, especially when lymph nodes are removed and patients must watch for swelling or arm symptoms afterward. Radiation then adds another layer of treatment intensity. For someone with HER2-positive disease, targeted therapy can substantially change the therapeutic outlook, but it also requires sustained adherence and monitoring. The benefit comes from persistence as much as from the drug itself.
Her account also shows how early presentation can change the clinical course. She sought help once the lump grew and became painful, and she was assessed quickly. Breast cancer screening and symptom awareness are two different safety nets, and both matter. Screening can detect disease before it declares itself physically, while self-recognition of a new lump can move symptomatic patients into the diagnostic pathway long before a delay allows more extensive spread. Bethan Read, a clinical leader in chemotherapy and oncology at Northampton Hospital, said people should attend screening appointments when invited, stay alert to bodily changes, and seek medical advice if something does not feel right.
For women in the NHS screening age range, invitations arrive every three years from age 50 to 71. That interval is not designed to catch every tumor instantly; it is intended to identify cancers early enough that treatment can be less extensive and outcomes better than they would be after a longer delay. The message is plain: do not wait for pain, size, or persistence to become dramatic before taking a new breast change seriously.
Royse also credited her husband, her two teenage sons, and Breast Friends Northamptonshire for helping her through treatment. Support groups often occupy a place that medical teams cannot fill entirely. They normalize side effects, reduce isolation, and offer practical guidance from people who have already sat through chemotherapy, surgery, and radiotherapy. For a patient with a new diagnosis, that shared experience can be as stabilizing as any prescription.
She has postponed plans to study for a doctorate in nursing focused on atrial fibrillation and arrhythmia at the University of Northampton. The interruption is temporary, but it reflects a common and often underappreciated consequence of cancer care: professional life pauses while treatment takes priority. Even for someone who understands illness from the inside, recovery demands time, energy, and patience that cannot be rushed.
Her case is a reminder that breast cancer care is not only about eradicating disease. It is also about preserving function, supporting the person through treatment, and keeping the door open to work, family life, and future plans after therapy ends. The challenge now is not diagnostic uncertainty. It is completing radiotherapy and ongoing systemic treatment while watching for toxicity, recurrence, and the slow return of normal life.